UK clinical trials - updated daily from ClinicalTrials.gov
Understand the key differences between targeted therapy and immunotherapy clinical trials and research opportunities
Drugs designed to target specific molecular features of cancer (EGFR inhibitors, BRAF inhibitors, PARP inhibitors). Requires biomarker testing for eligibility.
Stimulates the patient's own immune system to attack cancer. Checkpoint inhibitors are the most common class. Biomarker testing (PD-L1, TMB) helps predict response.
Targeted therapies require specific mutations. Immunotherapy depends on the tumour's immune environment. Both are precision medicine but work through different mechanisms.
Search our database of 29,000+ UK clinical trials matched to your condition and profile
Browse Disease PathwaysData sourced from ClinicalTrials.gov. Trial counts are approximate and updated regularly.
TrialConnect is a trading name of Clinical Vendor Compare Limited.
